Baillie Gifford & Co
NVO

Baillie Gifford & Co’s Novo Nordisk NVO Stock Holding History

Baillie Gifford & Co’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.93K Hold
82
– – ﹤0.01% 270
2026
Q1 		$3.01K Sell
82
-355
-81% -$16.8K ﹤0.01% 268
2025
Q4 		$22.2K Buy
437
+123
+39% +$6.29K ﹤0.01% 256
2025
Q3 		$17.4K Buy
314
+184
+142% +$10.8K ﹤0.01% 257
2025
Q2 		$8.97K Sell
130
-46
-26% -$3.13K ﹤0.01% 259
2025
Q1 		$12.2K Buy
176
+123
+232% +$10.2K ﹤0.01% 259
2024
Q4 		$4.56K Hold
53
– – ﹤0.01% 267
2024
Q3 		$6.31K Buy
53
+9
+20% +$1.2K ﹤0.01% 274
2024
Q2 		$6.28K Buy
44
+18
+69% +$2.38K ﹤0.01% 280
2024
Q1 		$3.34K Buy
+26
New +$3.1K ﹤0.01% 285

Other funds holding NVO

Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
EHC
Everett Harris & Co Los Angeles, California $8.14B AUM 14.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SRIM
Saratoga Research & Investment Management Saratoga, California $1.83B AUM 18.41% 1-Year Est. Return
MG
Markel Group Glen Allen, Virginia $13.1B AUM 15.62% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
OAM
Oppenheimer Asset Management New York $9.63B AUM 30.32% 1-Year Est. Return

Baillie Gifford & Co's NVO Position: Q2 2026 in Review

Baillie Gifford & Co held its Novo Nordisk (NVO) position steady in Q2 2026 at 82 shares worth $3.93K. The position accounts for ﹤0.01% of the portfolio, ranked #270.

Baillie Gifford & Co first reported a position in NVO in Q1 2024 and has held it in 10 quarters since. The position peaked at $22.2K in Q4 2025. 819 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Baillie Gifford & Co held 82 shares of Novo Nordisk worth $3.93K as of Q2 2026.
  • Baillie Gifford & Co left its Novo Nordisk share count unchanged in Q2 2026.
  • Novo Nordisk made up ﹤0.01% of Baillie Gifford & Co's portfolio in Q2 2026, its #270 holding.
  • Baillie Gifford & Co first reported a position in Novo Nordisk in Q1 2024 and has held it in 10 quarters since.
  • Baillie Gifford & Co's Novo Nordisk position peaked at $22.2K in Q4 2025.
  • 819 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Baillie Gifford & Co's 13F filing for Q2 2026, filed 6 Aug 2026.